Literature DB >> 30625476

Prevalence of Migraine in the Elderly: A Narrated Review.

Tissa Wijeratne1,2,3, Huiliang Melissa Tang4,5, David Crewther6,7, Sheila Crewther4,6.   

Abstract

Migraine is one of the most prevalent neurological disorders among all age groups including the elderly, but the incidence and prevalence of migraine tend to decrease with age. The clinical phenotype of migraine also appears to be different in the elderly patient group in comparison to the younger patient group, with elderly migraine appearing to be more often bilateral and associated with what has become known as "late-life migraine accompaniments. Furthermore, difficulty in the differentiation of migraine from vascular insults such as transient ischemic attacks and amyloid angiopathy and other multiple comorbidities, polypharmacy and age-related changes in pharmacodynamics and pharmacokinetics makes treatments for this cohort challenging but necessary, especially given the worldwide increase in life expectancy, and likelihood of migraine continuing to be a major personal and public health problem.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Calcitonin gene-related peptide; Elderly; Migraine; Prevalence

Year:  2019        PMID: 30625476     DOI: 10.1159/000494758

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  11 in total

Review 1.  Visual Processing During the Interictal Period Between Migraines: A Meta-Analysis.

Authors:  Timucin Sezai; Melanie J Murphy; Nina Riddell; Vinh Nguyen; Sheila G Crewther
Journal:  Neuropsychol Rev       Date:  2022-09-17       Impact factor: 6.940

2.  Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: a randomized, placebo-controlled trial.

Authors:  Hanie Matin; Farzaneh Taghian; Ahmad Chitsaz
Journal:  Neurol Sci       Date:  2022-02-03       Impact factor: 3.307

Review 3.  Episodic Migraine and Older Adults.

Authors:  Nina Riggins; Annika Ehrlich
Journal:  Curr Pain Headache Rep       Date:  2022-04-06

4.  Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.

Authors:  Virginia L Stauffer; Ira Turner; Phebe Kemmer; William Kielbasa; Kathleen Day; Martha Port; Tonya Quinlan; Angelo Camporeale
Journal:  J Headache Pain       Date:  2020-06-23       Impact factor: 7.277

5.  Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.

Authors:  Stephanie J Nahas; Steffen Naegel; Joshua M Cohen; Xiaoping Ning; Lindsay Janka; Verena Ramirez Campos; Lynda J Krasenbaum; Dagny Holle-Lee; David Kudrow; Christian Lampl
Journal:  J Headache Pain       Date:  2021-11-24       Impact factor: 7.277

6.  Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.

Authors:  Christian Lampl; Viktoria Kraus; Katrina Lehner; Brett Loop; Mahan Chehrenama; Zofia Maczynska; Shannon Ritter; Jan Klatt; Josefin Snellman
Journal:  J Headache Pain       Date:  2022-08-18       Impact factor: 8.588

7.  Primary headaches increase the risk of dementias: An 8-year nationwide cohort study.

Authors:  Seon-Jip Kim; Sang Min Park; Hyun-Jae Cho; Ji Woon Park
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

8.  Factors Associated with Over-the-Counter Analgesic Overuse among Individuals Experiencing Headache.

Authors:  Maram Alshareef
Journal:  Clin Pract       Date:  2022-09-05

9.  Eptinezumab for migraine prevention in patients 50 years or older.

Authors:  Vincent Martin; Cristina Tassorelli; Anders Ettrup; Joe Hirman; Roger Cady
Journal:  Acta Neurol Scand       Date:  2022-02-26       Impact factor: 3.915

10.  Scientific Knowledge Graph of Acupuncture for Migraine: A Bibliometric Analysis from 2000 to 2019.

Authors:  Yanqing Zhao; Li Huang; Meijuan Liu; Han Gao; Wentao Li
Journal:  J Pain Res       Date:  2021-06-30       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.